Validating the PVD-B65 Risk Score for Predicting One-Year Outcomes in Adults With Chronic Lung Disease and Pulmonary Hypertension

What this Trial Is About

Researchers are evaluating the PVD-B65 risk score to predict one-year mortality in adults with chronic lung disease and pulmonary hypertension CLD-PH. This prospective observational study aims to validate the score, which uses factors like pulmonary fibrosis, pulmonary vascular resistance, walking distance, peptide levels, and age to classify risk. The study also explores how the score predicts clinical worsening and whether standard treatments affect survival. Participants will have their PVD-B65 score assigned based on standard diagnostic testing at diagnosis or referral. There is no experimental treatment the study only observes patients following usual care. The study will track health changes including pulmonary hypertension severity and lung function through tests like right-heart catheterization, echocardiograms, and lung function tests over one year. During the study, participants will be followed for one year with assessments every 3 to 6 months to monitor mortality, clinical worsening, and changes in risk score and lung health. Outcomes include survival status, hospitalizations, oxygen needs, therapy changes, and lung and heart function. The study team will collect data from routine care and tests to understand how well the PVD-B65 score predicts outcomes in these patients.

Prospective Validation of the Novel PVD-B65 Risk Score in Patients With Chronic Lung Disease and Pulmonary Hypertension